The North America Cell Sorting Market is poised for robust growth, driven by technological advancements and increased demand for precision medicine. The market size was valued at USD 910 Million in 2025 and is expected to reach USD 2,650 Million by 2035, registering a CAGR of 10.6% over the forecast period.
The economic impact of tariffs on "North America Cell Sorting Market".
Market Growth Drivers
Technological advancements in cell sorting technologies, such as microfluidic cell sorting and high-throughput flow cytometry, are enabling more precise and faster cell separation. Companies like BD Biosciences have introduced next-generation instruments that improve accuracy and efficiency, making cell sorting increasingly accessible for research and clinical applications.
Rising prevalence of chronic and infectious diseases such as cancer and HIV is boosting demand for advanced diagnostic tools. For instance, Thermo Fisher Scientific’s expansion in cell separation kits addresses the need for personalized treatments and real-time monitoring, directly impacting the rapid adoption of cell sorting devices across North America.
Market Trends
The integration of artificial intelligence (AI) and machine learning in cell sorting systems is a growing trend. Companies like Sony Biotechnology are leveraging AI to improve gating accuracy, reduce errors, and automate data analysis, significantly streamlining workflows in both research and clinical laboratories.
Increasing partnership and collaboration between biopharmaceutical companies and academic institutions are driving innovation in the cell sorting market. For example, Beckman Coulter Life Sciences recently partnered with multiple universities to develop novel protocols for sorting rare cell types, facilitating breakthroughs in regenerative medicine and cell therapy research.
Market Opportunities
The rise of cell-based therapies and regenerative medicine offers significant growth opportunities for the cell sorting market. Companies like Miltenyi Biotec are investing in novel sorting technologies to support the scale-up of CAR-T and stem cell therapy manufacturing.
Emergence of point-of-care cell sorting devices presents untapped market segments, particularly in decentralized and outreach healthcare settings, creating new revenue streams for key players.
North America Cell Sorting Market Revenue (2020-2035, USD Million)
The market revenue chart highlights steady growth in the North America Cell Sorting Market from 2020 to 2035. Starting at USD 480 Million in 2020, the market witnesses incremental rises due to ongoing R&D, expanded adoption in clinical diagnostics, and a surge in personalized medicine approaches. The growth curve becomes steeper post-2025, reflecting the impact of automation and AI integration. By 2035, revenue is projected to reach approximately USD 2,650 Million, signaling increased investment and market maturity.
North America Cell Sorting Market Share by Region (%) - 2025
The 2025 market share pie chart reveals the United States leading with a significant 68% share, driven by advanced healthcare infrastructure and research funding. Canada follows with 18%, benefitting from supportive government investments in biotechnology. Mexico holds 7%, while the Rest of North America, including Caribbean nations and peripheral US territories, collectively make up the remaining 7%. Concentration in the United States is expected due to early technology adoption and robust clinical research activities.
Recent Developments in North America Cell Sorting Market
In March 2024, BD Biosciences launched the BD FACSymphony™ A1 Cell Sorter, a next-generation benchtop instrument offering enhanced flexibility and sensitivity for multi-parameter flow cytometry. The system leverages advanced fluorochrome detection and automated quality controls, aiming to improve reproducibility in complex research experiments and streamline cell sorting protocols for labs of all sizes.
In May 2024, Thermo Fisher Scientific announced its partnership with the Dana-Farber Cancer Institute to co-develop precision cell sorting solutions for immunotherapy applications. The joint effort focuses on designing custom kits that isolate specific immune cell subsets, facilitating innovative cancer treatments and enabling researchers to accelerate translational research for new therapies.
In April 2024, Beckman Coulter Life Sciences introduced an AI-powered software upgrade for its CytoFLEX SRT cell sorter, allowing users to automate standard gating processes and reducing sample analysis time by 30%. The software also integrates with electronic lab notebooks, supporting better sample tracking and compliance for clinical and pharmaceutical laboratories.
Press Releases